New York, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Industry" - https://www.reportlinker.com/p05443604/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market to Reach $51.9 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics estimated at US$28.7 Billion in the year 2022, is projected to reach a revised size of US$51.9 Billion by 2030, growing at aCAGR of 7.7% over the period 2022-2030. Stimulant, one of the segments analyzed in the report, is projected to record 7.2% CAGR and reach US$43 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Non-Stimulant segment is readjusted to a revised 10.2% CAGR for the next 8-year period.
The U.S. Market is Estimated at $8.4 Billion, While China is Forecast to Grow at 7.2% CAGR
The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics market in the U.S. is estimated at US$8.4 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$9 Billion by the year 2030 trailing a CAGR of 7.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.9% and 6.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR.
Select Competitors (Total 27 Featured)
- Alcobra Ltd.
- Amarantus Bioscience Holdings, Inc.
- Curemark, LLC
- Eli Lilly and Company
- Intellipharmaceutics International, Inc.
- Janssen Global Services, LLC
- Mallinckrodt PLC
- Mylan NV
- Neos Therapeutics, Inc.
- Neurovance, Inc.
- Noven Pharmaceuticals, Inc.
- Pfizer Inc.
- Shire plc
- Supernus Pharmaceuticals, Inc.
- Tris Pharma, Inc.
Read the full report: https://www.reportlinker.com/p05443604/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
ADHD Therapeutics: A Primer
Recent Market Activity
ADHD Therapeutics Market Outlook
Factors Driving ADHD Therapeutics Market
Changes in Insurance Coverage
Addition of Formal Guidelines
Low Diagnosis Threshold
Advancements in Field of Medicine
Unmet Needs
Launch of Pipeline Drugs
Factors Inhibiting ADHD Therapeutics Market
Side Effects Related to Use of Stimulants to Treat ADHD
Under-diagnosis of ADHD Condition
Reduced Availability of Non-Stimulants in Certain Geographies
Competitive Landscape
Major ADHD Medications Available in the Market
ADHD Medications Approved by FDA
Patent Validity for Major ADHD Drugs
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics -
Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
Alcobra Ltd. (Israel)
Amarantus Bioscience Holdings, Inc. (US)
Amedra Pharmaceuticals LLC (US)
Curemark, LLC. (US)
Eli Lilly and Company (US)
Intellipharmaceutics International, Inc. (US)
Janssen Global Services, LLC (US)
Mallinckrodt PLC (Ireland)
Mylan N.V. (The Netherlands)
Neos Therapeutics, Inc. (US)
Neurovance, Inc. (US)
Noven Pharmaceuticals, Inc. (US)
Pfizer Inc. (US)
Shire plc (Ireland)
Supernus Pharmaceuticals, Inc. (US)
Tris Pharma, Inc. (US)
3. MARKET TRENDS & DRIVERS
Biological Psychiatry Gaining Ground
Social Media Drives Heightened Awareness
Stimulants Dominate the Market but Non-Stimulants Inching Their
Way to Popularity
Robust Growth in Pediatric ADHD Therapeutic Market to Propel
Overall Market
Strategic Alliances
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2022 through 2030 and
% CAGR
Table 2: World Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2021 and % CAGR
Table 3: World 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region -
Percentage Breakdown of Value Sales for USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets for Years
2012, 2023 & 2030
Table 4: World Recent Past, Current & Future Analysis for
Stimulant by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR
Table 5: World Historic Review for Stimulant by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2021 and % CAGR
Table 6: World 18-Year Perspective for Stimulant by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2023 & 2030
Table 7: World Recent Past, Current & Future Analysis for
Non-Stimulant by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR
Table 8: World Historic Review for Non-Stimulant by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2021 and % CAGR
Table 9: World 18-Year Perspective for Non-Stimulant by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2023 & 2030
Table 10: World Recent Past, Current & Future Analysis for
Adult by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2022 through 2030 and
% CAGR
Table 11: World Historic Review for Adult by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2021 and % CAGR
Table 12: World 18-Year Perspective for Adult by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2023 & 2030
Table 13: World Recent Past, Current & Future Analysis for
Children by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR
Table 14: World Historic Review for Children by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2021 and % CAGR
Table 15: World 18-Year Perspective for Children by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2023 & 2030
Table 16: World Recent Past, Current & Future Analysis for
Retail Pharmacy by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR
Table 17: World Historic Review for Retail Pharmacy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2021 and
% CAGR
Table 18: World 18-Year Perspective for Retail Pharmacy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2023 & 2030
Table 19: World Recent Past, Current & Future Analysis for
Hospital Pharmacy by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR
Table 20: World Historic Review for Hospital Pharmacy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2021 and
% CAGR
Table 21: World 18-Year Perspective for Hospital Pharmacy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2023 & 2030
Table 22: World Attention Deficit Hyperactivity Disorder (ADHD)
Therapeutics Market Analysis of Annual Sales in US$ Million for
Years 2012 through 2030
III. MARKET ANALYSIS
UNITED STATES
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics
Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in the United States for 2023 (E)
Table 23: USA Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Drug Type - Stimulant and Non-Stimulant - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR
Table 24: USA Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2021 and %
CAGR
Table 25: USA 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Percentage Breakdown of Value Sales for Stimulant and
Non-Stimulant for the Years 2012, 2023 & 2030
Table 26: USA Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Demography - Adult and Children - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 27: USA Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Adult and Children Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2021 and % CAGR
Table 28: USA 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Percentage Breakdown of Value Sales for Adult and Children for
the Years 2012, 2023 & 2030
Table 29: USA Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Distribution Channel - Retail Pharmacy and Hospital Pharmacy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 30: USA Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Retail Pharmacy and Hospital Pharmacy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 31: USA 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Percentage Breakdown of Value Sales for Retail
Pharmacy and Hospital Pharmacy for the Years 2012, 2023 & 2030
CANADA
Table 32: Canada Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Drug Type - Stimulant and Non-Stimulant - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR
Table 33: Canada Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2021 and %
CAGR
Table 34: Canada 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Percentage Breakdown of Value Sales for Stimulant and
Non-Stimulant for the Years 2012, 2023 & 2030
Table 35: Canada Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Demography - Adult and Children - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 36: Canada Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Adult and Children Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2021 and % CAGR
Table 37: Canada 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Percentage Breakdown of Value Sales for Adult and Children for
the Years 2012, 2023 & 2030
Table 38: Canada Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Distribution Channel - Retail Pharmacy and Hospital Pharmacy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 39: Canada Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Retail Pharmacy and Hospital Pharmacy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 40: Canada 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Percentage Breakdown of Value Sales for Retail
Pharmacy and Hospital Pharmacy for the Years 2012, 2023 & 2030
JAPAN
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics
Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in Japan for 2023 (E)
Table 41: Japan Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Drug Type - Stimulant and Non-Stimulant - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR
Table 42: Japan Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2021 and %
CAGR
Table 43: Japan 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Percentage Breakdown of Value Sales for Stimulant and
Non-Stimulant for the Years 2012, 2023 & 2030
Table 44: Japan Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Demography - Adult and Children - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 45: Japan Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Adult and Children Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2021 and % CAGR
Table 46: Japan 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Percentage Breakdown of Value Sales for Adult and Children for
the Years 2012, 2023 & 2030
Table 47: Japan Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Distribution Channel - Retail Pharmacy and Hospital Pharmacy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 48: Japan Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Retail Pharmacy and Hospital Pharmacy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 49: Japan 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Percentage Breakdown of Value Sales for Retail
Pharmacy and Hospital Pharmacy for the Years 2012, 2023 & 2030
CHINA
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics
Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in China for 2023 (E)
Table 50: China Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Drug Type - Stimulant and Non-Stimulant - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR
Table 51: China Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2021 and %
CAGR
Table 52: China 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Percentage Breakdown of Value Sales for Stimulant and
Non-Stimulant for the Years 2012, 2023 & 2030
Table 53: China Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Demography - Adult and Children - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 54: China Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Adult and Children Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2021 and % CAGR
Table 55: China 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Percentage Breakdown of Value Sales for Adult and Children for
the Years 2012, 2023 & 2030
Table 56: China Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Distribution Channel - Retail Pharmacy and Hospital Pharmacy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 57: China Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Retail Pharmacy and Hospital Pharmacy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 58: China 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Percentage Breakdown of Value Sales for Retail
Pharmacy and Hospital Pharmacy for the Years 2012, 2023 & 2030
EUROPE
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics
Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in Europe for 2023 (E)
Table 59: Europe Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 60: Europe Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region -
France, Germany, Italy, UK and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 61: Europe 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region -
Percentage Breakdown of Value Sales for France, Germany,
Italy, UK and Rest of Europe Markets for Years 2012, 2023 &
2030
Table 62: Europe Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Drug Type - Stimulant and Non-Stimulant - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR
Table 63: Europe Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2021 and %
CAGR
Table 64: Europe 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Percentage Breakdown of Value Sales for Stimulant and
Non-Stimulant for the Years 2012, 2023 & 2030
Table 65: Europe Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Demography - Adult and Children - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 66: Europe Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Adult and Children Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2021 and % CAGR
Table 67: Europe 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Percentage Breakdown of Value Sales for Adult and Children for
the Years 2012, 2023 & 2030
Table 68: Europe Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Distribution Channel - Retail Pharmacy and Hospital Pharmacy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 69: Europe Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Retail Pharmacy and Hospital Pharmacy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 70: Europe 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Percentage Breakdown of Value Sales for Retail
Pharmacy and Hospital Pharmacy for the Years 2012, 2023 & 2030
FRANCE
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics
Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in France for 2023 (E)
Table 71: France Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Drug Type - Stimulant and Non-Stimulant - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR
Table 72: France Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2021 and %
CAGR
Table 73: France 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Percentage Breakdown of Value Sales for Stimulant and
Non-Stimulant for the Years 2012, 2023 & 2030
Table 74: France Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Demography - Adult and Children - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 75: France Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Adult and Children Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2021 and % CAGR
Table 76: France 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Percentage Breakdown of Value Sales for Adult and Children for
the Years 2012, 2023 & 2030
Table 77: France Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Distribution Channel - Retail Pharmacy and Hospital Pharmacy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 78: France Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Retail Pharmacy and Hospital Pharmacy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 79: France 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Percentage Breakdown of Value Sales for Retail
Pharmacy and Hospital Pharmacy for the Years 2012, 2023 & 2030
GERMANY
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics
Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in Germany for 2023 (E)
Table 80: Germany Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Drug Type - Stimulant and Non-Stimulant - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR
Table 81: Germany Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2021 and %
CAGR
Table 82: Germany 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Percentage Breakdown of Value Sales for Stimulant and
Non-Stimulant for the Years 2012, 2023 & 2030
Table 83: Germany Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Demography - Adult and Children - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 84: Germany Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Adult and Children Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2021 and % CAGR
Table 85: Germany 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Percentage Breakdown of Value Sales for Adult and Children for
the Years 2012, 2023 & 2030
Table 86: Germany Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Distribution Channel - Retail Pharmacy and Hospital Pharmacy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 87: Germany Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Retail Pharmacy and Hospital Pharmacy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 88: Germany 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Percentage Breakdown of Value Sales for Retail
Pharmacy and Hospital Pharmacy for the Years 2012, 2023 & 2030
ITALY
Table 89: Italy Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Drug Type - Stimulant and Non-Stimulant - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR
Table 90: Italy Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2021 and %
CAGR
Table 91: Italy 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Percentage Breakdown of Value Sales for Stimulant and
Non-Stimulant for the Years 2012, 2023 & 2030
Table 92: Italy Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Demography - Adult and Children - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 93: Italy Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Adult and Children Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2021 and % CAGR
Table 94: Italy 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Percentage Breakdown of Value Sales for Adult and Children for
the Years 2012, 2023 & 2030
Table 95: Italy Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Distribution Channel - Retail Pharmacy and Hospital Pharmacy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 96: Italy Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Retail Pharmacy and Hospital Pharmacy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 97: Italy 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Percentage Breakdown of Value Sales for Retail
Pharmacy and Hospital Pharmacy for the Years 2012, 2023 & 2030
UNITED KINGDOM
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics
Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in the United Kingdom for 2023 (E)
Table 98: UK Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Drug Type - Stimulant and Non-Stimulant - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR
Table 99: UK Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2021 and %
CAGR
Table 100: UK 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Percentage Breakdown of Value Sales for Stimulant and
Non-Stimulant for the Years 2012, 2023 & 2030
Table 101: UK Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Demography - Adult and Children - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 102: UK Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Adult and Children Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2021 and % CAGR
Table 103: UK 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Percentage Breakdown of Value Sales for Adult and Children for
the Years 2012, 2023 & 2030
Table 104: UK Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Distribution Channel - Retail Pharmacy and Hospital Pharmacy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 105: UK Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Retail Pharmacy and Hospital Pharmacy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 106: UK 18-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Percentage Breakdown of Value Sales for Retail
Pharmacy and Hospital Pharmacy for the Years 2012, 2023 & 2030
REST OF EUROPE
Table 107: Rest of Europe Recent Past, Current & Future
Analysis for Attention Deficit Hyperactivity Disorder (ADHD)
Therapeutics by Drug Type - Stimulant and Non-Stimulant -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 108: Rest of Europe Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2021 and %
CAGR
Table 109: Rest of Europe 18-Year Perspective for Attention
Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Percentage Breakdown of Value Sales for Stimulant and
Non-Stimulant for the Years 2012, 2023 & 2030
Table 110: Rest of Europe Recent Past, Current & Future
Analysis for Attention Deficit Hyperactivity Disorder (ADHD)
Therapeutics by Demography - Adult and Children - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 111: Rest of Europe Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Adult and Children Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2021 and % CAGR
Table 112: Rest of Europe 18-Year Perspective for Attention
Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Demography - Percentage Breakdown of Value Sales for Adult and
Children for the Years 2012, 2023 & 2030
Table 113: Rest of Europe Recent Past, Current & Future
Analysis for Attention Deficit Hyperactivity Disorder (ADHD)
Therapeutics by Distribution Channel - Retail Pharmacy and
Hospital Pharmacy - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 114: Rest of Europe Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Retail Pharmacy and Hospital Pharmacy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 115: Rest of Europe 18-Year Perspective for Attention
Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Distribution Channel - Percentage Breakdown of Value Sales for
Retail Pharmacy and Hospital Pharmacy for the Years 2012, 2023 &
2030
ASIA-PACIFIC
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics
Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in Asia-Pacific for 2023 (E)
Table 116: Asia-Pacific Recent Past, Current & Future Analysis
for Attention Deficit Hyperactivity Disorder (ADHD)
Therapeutics by Drug Type - Stimulant and Non-Stimulant -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05443604/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
